Finally, in the 2000s, the Novartis compound STI571 (later known as imatinib mesylate), which showed surprising results by selectively inhibiting BCR/ABL1 at micromolar concentrations, was approved as therapy for CML [42,43]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.